Online now! Online now! Covalent PPARγ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARγ/RXRα-activated urothelial carcinoma #chembiol
PPARγ has emerged as a promising target for the treatment of muscle-invasive urothelial carcinoma (MIUC). Stuckey et al. report the discovery of FX-909, a covalent inverse agonist of PPARγ suitable for clinical development and capable of suppressing PPARG-driven growth in xenograft models of MIUC.
